Following the Onglyza (Saxagliptin) and Victoza (Liraglutide) FDA Advisory Committee meetings last week, we have combined our analysis of the panels, the impact on other drugs in development and resulting updates to our recent Diabetes Timing Update event.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.